enGene Holdings Inc. (NASDAQ:ENGNW) Sees Significant Growth in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totaling 40,902 shares, a growth of 10,151.1% from the April 30th total of 399 shares. Based on an average daily trading volume, of 41,526 shares, the days-to-cover ratio is currently 1.0 days.

enGene Stock Down 3.1%

Shares of ENGNW stock opened at $0.25 on Friday. The stock has a 50-day simple moving average of $1.63 and a 200 day simple moving average of $2.45. enGene has a fifty-two week low of $0.11 and a fifty-two week high of $4.20.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.